Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dollars For Donuts: PhRMA's $80 Bil. Coup In Health Care Reform

Executive Summary

PhRMA's commitment to contribute $80 billion toward health systems savings over the next 10 years looks like an important tactical win for the brand name industry entering the critical phase of the health reform debate

You may also be interested in...

Pharma Outpaces All Other Industries In US Federal Lobbying Spending

Over the past 20 years, the pharmaceutical industry has notched a series of wins with its extraordinary federal lobbying expenditures and campaign contributions. A new JAMA Internal Medicine study examines spending from 1999-2018.

Sen. Baucus Still Has Ambitious Agenda: Tax Reform, Deficit Reduction, ACA

Finance Committee chairman decides not to seek re-election in 2014. He has a history of working productively with the drug industry on major legislation such as health reform, the Medicare Modernization Act and PDUFA reauthorizations.

Who’s Who On The Joint Select Committee On Deficit Reduction

The Budget Control Act created a 12-member bicameral panel charged with finding at least $1.2 trillion to cut from federal spending. The top Democrat and top Republican in each chamber of Congress appointed three members to serve on the joint committee. The Committee needs to make its legislative proposal by Thanksgiving, with only a simple majority needed to send the fiscal package to both chambers for approval. President Obama would then have to sign the bill by Jan. 15, 2012. A failure to accomplish this will trigger automatic spending cuts across all government programs as defined by the BCA (“Beware The Debt Deal’s Spending Cut Trigger: Medicare Part D and B Provider Pay Would Drop,” “The Pink Sheet” DAILY, Aug. 2, 2011). Health care related issues are expected to be a significant part of the discussions within the committee, including Medicaid-level rebates for drugs used by dual eligibles in the Medicare Part D program.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts